Share This Page
Drug Price Trends for NDC 16714-0969
✉ Email this page to a colleague
Average Pharmacy Cost for 16714-0969
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| TESTOSTERONE 1.62% (2.5 G) PKT | 16714-0969-02 | 2.44266 | GM | 2025-12-17 |
| TESTOSTERONE 1.62% (2.5 G) PKT | 16714-0969-02 | 2.29294 | GM | 2025-11-19 |
| TESTOSTERONE 1.62% (2.5 G) PKT | 16714-0969-02 | 2.24459 | GM | 2025-10-22 |
| TESTOSTERONE 1.62% (2.5 G) PKT | 16714-0969-02 | 2.23112 | GM | 2025-09-17 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 16714-0969
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC 16714-0969
Introduction
The pharmaceutical landscape surrounding NDC 16714-0969—a distinctive code assigned by the National Drug Code (NDC) system—entails a comprehensive assessment of current market dynamics, competitive positioning, regulatory factors, and price trajectory forecasts. This analysis provides industry professionals with strategic insights necessary for informed decision-making, including pricing strategies, market entry considerations, and competitive intelligence.
Drug Overview and Regulatory Status
NDC 16714-0969 pertains to a specific pharmaceutical entity authorized for therapeutic use. As per FDA databases, this code corresponds to a [insert drug name], classified under [drug class], with indications primarily in [therapeutic area]. The device's regulatory status as of the latest update indicates [approval, supplemental approval, or pending review].
Critical regulatory milestones influence market potential: approvals facilitate commercialization, while optional or pending approvals may delay entry and impact valuation. Ongoing regulatory scrutiny also shapes post-market surveillance costs and pricing flexibility.
Market Landscape and Demand Drivers
Therapeutic Area and Epidemiological Trends
The drug's target condition significantly impacts its market size. For example, [if applicable, e.g., oncology, rare diseases, cardiovascular disorders] maintains a growing incidence, driven by demographic shifts, increased screening, or unmet medical needs. Particularly:
- Prevalence and Incidence: Recent epidemiological studies indicate a [X]% increase over the past [Y] years in [target patient population].
- Unmet Needs: Existing therapies exhibit [limitations such as efficacy, safety, administration routes], paving the way for innovative interventions like [product in question].
Competitive Dynamics
The competitive environment comprises both branded and generic therapeutic options. Key competitors include [list top competitors, e.g., X, Y, Z]. Market share distribution hinges on factors such as efficacy, safety profile, pricing, convenience, and provider familiarity.
Recent launches or pipeline products threaten to erode market share if NDC 16714-0969 does not demonstrate clear advantages. The drug’s differentiation—such as novel mechanism, improved compliance, or reduced side effects—serves as a pivotal competitive lever.
Market Access and Reimbursement
Coverage policies enacted by CMS, private insurers, and pharmacy benefit managers (PBMs) will impose constraints or afford opportunities. Reimbursement levels influence net drug pricing; high coverage likelihood boosts adoption but pressures list prices. Payer negotiations and formulary placements are essential in projection models.
Price Trends and Historical Data
Current Pricing Landscape
Based on publicly available data, the average wholesale price (AWP) for drugs within this category varies from $X to $Y per unit, with [specific brand or generic] leading the market. Manufacturer suggested retail prices (MSRP) and actual transaction prices may differ due to discounts, rebates, and negotiated rates.
Factors Influencing Price Dynamics
- Regulatory approvals and indications: Broader approval indications tend to justify higher prices.
- Market exclusivity: Patent protections or exclusivity periods sustain pricing power.
- Manufacturing costs: Innovation, scale, and supply chain efficiencies influence baseline pricing.
Recent Price Trends
In the past [Y] years, prices for comparable drugs have experienced [steady growth, stabilization, or decline], driven largely by [e.g., biosimilar entries, payer pressure, policy changes]. Notably, some therapeutics saw [X]% annual price increases, underscoring inflationary pressures and value-based pricing adjustments.
Price Projections (Next 3–5 Years)
Conservative Scenario
Under conservative assumptions—moderate uptake, stable competition, and regulatory continuity—NDC 16714-0969 is projected to maintain a list price in the vicinity of $X to $Y per unit, with annual increases capped at [X]% due to payer negotiations and market adjustments.
Optimistic Scenario
In a scenario where the drug secures rapid reimbursement approval, demonstrates superior clinical outcomes, and faces limited competition, prices could reach $Z with annual growth rates of [Y]%, primarily driven by inflationary pressures and premium positioning benefits.
Competitive Market Entry and Biosimilar Impact
The entry of biosimilars or generics could significantly reduce prices—potentially by [X]% to Y]%—within [Y] years post-launch. This downward pressure necessitates flexible pricing strategies, early value demonstrations, and robust pharmacoeconomic evidence to sustain premium pricing where feasible.
Implications for Stakeholders
- Manufacturers should plan for strategic pricing adjustments aligned with market maturation.
- Payers seek value-based arrangements to optimize spend.
- Providers and patients benefit from affordability and access, influencing uptake trajectories.
Factors Affecting Future Price Trajectories
- Regulatory decisions: Expanded indications can support higher prices.
- Clinical trial results: Demonstration of superiority influences reimbursement negotiations.
- Market penetration: Early adoption rates shape long-term pricing potential.
- Healthcare policy shifts: Legislation targeting drug affordability could impose price controls or value-based pricing mandates.
- Generic/biosimilar competition: These entities' timely market entry will impact pricing strategies and potential revenue streams.
Key Takeaways
- NDC 16714-0969 resides within a dynamic therapeutic landscape where unmet needs foster significant market potential.
- The competitive environment and regulatory factors critically influence current and future pricing strategies.
- Historical data suggests a trend of moderate price increases, but biosimilar and generic entrants threaten to reduce prices substantially within the next 3–5 years.
- Strategic pricing will hinge on demonstrating clinical value, navigating regulatory pathways, and adapting to payer policies.
- Manufacturers should develop flexible, evidence-based pricing models that can withstand market evolutions to optimize revenue lifecycle.
FAQs
Q1: What is the primary therapeutic indication for NDC 16714-0969?
A: The drug addresses [specific condition], supported by its approved indications and clinical trial data.
Q2: How does the current market competition influence the pricing of this drug?
A: Monopoly status, patent protection, and differentiation determine pricing power, while entry of biosimilars or generics exerts downward pressure.
Q3: What are the key regulatory considerations affecting the drug's marketability?
A: Regulatory approvals, supplemental indications, and post-market surveillance requirements are vital in shaping commercial strategy and pricing.
Q4: How might changes in healthcare policy impact the drug's future price?
A: Legislation promoting drug affordability, such as price caps or value-based pricing mandates, could restrict profit margins but also expand access.
Q5: When can manufacturers expect to see biosimilar or generic competition?
A: Typically within 8–12 years post-patent, depending on regulatory exclusivity periods and market entry strategies.
References
- [FDA Database]: Detailed information about NDC 16714-0969.
- [Market Reports]: Epidemiological and market trend analyses relevant to the drug’s therapeutic area.
- [Pricing Data Sources]: Wholesale and retail pricing trends from IQVIA, SSR Health, or equivalent datasets.
- [Regulatory and Policy Briefs]: Insights into evolving legislation affecting drug pricing.
- [Competitive Landscape Analyses]: Market share data and pipeline reports for comparable therapeutics.
This analysis intends to serve as a strategic guide for stakeholders to assess market opportunities and develop adaptable pricing frameworks in light of evolving market conditions for NDC 16714-0969.
More… ↓
